BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37308298)

  • 1. Absorption, Distribution, Metabolism, and Excretion of [
    James AD; Kulmatycki K; Poller B; Romeo AA; Van Lier JJ; Klein K; Pearson D
    Drug Metab Dispos; 2023 Jul; 51(7):873-883. PubMed ID: 37308298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
    Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
    Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.
    Glaenzel U; Jin Y; Hansen R; Schroer K; Rahmanzadeh G; Pfaar U; Jaap van Lier J; Borell H; Meissner A; Camenisch G; Zhao S
    Drug Metab Dispos; 2020 Oct; 48(10):873-885. PubMed ID: 32665418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism and Disposition of Siponimod, a Novel Selective S1P
    Glaenzel U; Jin Y; Nufer R; Li W; Schroer K; Adam-Stitah S; Peter van Marle S; Legangneux E; Borell H; James AD; Meissner A; Camenisch G; Gardin A
    Drug Metab Dispos; 2018 Jul; 46(7):1001-1013. PubMed ID: 29735753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Disposition, and Biotransformation of [
    Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R
    Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biotransformation Pathways and Metabolite Profiles of Oral [
    Pusalkar S; Zhou X; Li Y; Cohen L; Yang JJ; Balani SK; Xia C; Shyu WC; Lu C; Venkatakrishnan K; Chowdhury SK
    Drug Metab Dispos; 2020 Mar; 48(3):217-229. PubMed ID: 31911485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Absorption, Metabolism, and Excretion of a Single Oral 1-mg Dose of Tropifexor in Healthy Male Subjects and the Concentration Dependence of Tropifexor Metabolism.
    Wang-Lakshman L; Miao Z; Wang L; Gu H; Kagan M; Gu J; McNamara E; Walles M; Woessner R; Camenisch G; Einolf HJ; Chen J
    Drug Metab Dispos; 2021 Jul; 49(7):548-562. PubMed ID: 33952610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
    Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
    Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers.
    James A; Blumenstein L; Glaenzel U; Jin Y; Demailly A; Jakab A; Hansen R; Hazell K; Mehta A; Trandafir L; Swart P
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):751-60. PubMed ID: 26254025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and ADME Characterization of Intravenous and Oral [
    Zamek-Gliszczynski MJ; Kenworthy D; Bershas DA; Sanghvi M; Pereira AI; Mudunuru J; Crossman L; Pirhalla JL; Thorpe KM; Dennison JMTJ; McLaughlin MM; Allinder M; Swift B; O'Connor-Semmes RL; Young GC
    Drug Metab Dispos; 2021 Dec; 49(12):1109-1117. PubMed ID: 34625435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
    Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
    Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro.
    Pearson D; Weiss HM; Jin Y; Jaap van Lier J; Erpenbeck VJ; Glaenzel U; End P; Woessner R; Eggimann F; Camenisch G
    Drug Metab Dispos; 2017 Jul; 45(7):817-825. PubMed ID: 28442499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
    Mukai H; Sugimoto T; Ago M; Morino A
    Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome.
    Kavanagh D; Greenbaum LA; Bagga A; Karki RG; Chen CW; Vasudevan S; Charney A; Dahlke M; Fakhouri F
    Kidney Int Rep; 2023 Jul; 8(7):1332-1341. PubMed ID: 37441479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
    Schwab D; Portron A; Backholer Z; Lausecker B; Kawashima K
    Clin Pharmacokinet; 2013 Jun; 52(6):463-73. PubMed ID: 23494983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of the HIV-1 Maturation Inhibitor GSK3640254 Using an Intravenous Microtracer Combined with EnteroTracker for Biliary Sampling.
    Wen B; Zhang Y; Young GC; Kenworthy D; Pereira A; Pirhalla J; Doyle J; Jordon B; Zhan J; Johnson M
    Drug Metab Dispos; 2022 Nov; 50(11):1442-1453. PubMed ID: 36153007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers.
    O'Donnell J; Lawrence K; Vishwanathan K; Hosagrahara V; Mueller JP
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism and Disposition of Hepatitis C Polymerase Inhibitor Dasabuvir in Humans.
    Shen J; Serby M; Reed A; Lee AJ; Menon R; Zhang X; Marsh K; Wan X; Kavetskaia O; Fischer V
    Drug Metab Dispos; 2016 Aug; 44(8):1139-47. PubMed ID: 27179126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism and Disposition of Pan-Genotypic Inhibitor of Hepatitis C Virus NS5A Ombitasvir in Humans.
    Shen J; Serby M; Surber B; Lee AJ; Ma J; Badri P; Menon R; Kavetskaia O; de Morais SM; Sydor J; Fischer V
    Drug Metab Dispos; 2016 Aug; 44(8):1148-57. PubMed ID: 27179128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
    Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
    Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.